0022 GMT - The idea that fitness wearables or weight-loss drugs could create a step-change in demand for ResMed is too underdeveloped to incorporate into earnings forecasts, Wilsons analyst Shane Storey says. Cutting his recommendation on the breath-tech provider to market weight from overweight, Storey concedes that the growing use of GLP-1 drugs is a potential tailwind to the sleep industry, but thinks its impact can't yet be predicted. He writes in a note that ResMed's manufacturing and procurement initiatives, and scale benefits, will materialize in fiscal 2026 and fiscal 2027. Wilsons lifts its target price by 1.5% to A$42.82. Shares are down 3.2% at A$38.90. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
February 02, 2025 19:22 ET (00:22 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.